Eli Lilly's defining moves.
The defining strategic moves at Eli Lilly — each one explained and grounded in the record.
The Pricing Play · Pricing
Lilly Sells the Same Drug at $1,086 and $299. The Gap Is the Strategy.
Eli Lilly lists Zepbound at $1,086.37 a month and sells the same molecule direct-to-consumer for as low as $299. That isn't a discount war with itself - it's a tollgate built to crowd out compounders and get ahead of the government.
8 min
The Moat Anatomy · Moat Anatomy
Lilly's Real Moat Isn't the Molecule. It's the Concrete It Poured Before Anyone Said Yes.
In 2020 - years before the FDA approved either drug - Eli Lilly began building tirzepatide factories 'at risk.' By 2025 it had pledged over $50 billion to U.S. manufacturing. The patent isn't the moat. The capital cycle no rival can compress is.
8 min
The Moat Anatomy · Competitive Moats
Everyone Thinks Lilly Is Protected by a Patent. The Patent Is the Weakest Wall It Has.
Lilly's tirzepatide overtook Keytruda as the world's top-selling drug, and the obvious story is the patent that expires in 2036. But the patent is the least durable thing protecting Lilly - the real moat is a $50B factory you can't build in time.
8 min